Hepatitis C usually causes no symptoms for years while it quietly damages the liver, which is why screening is recommended for all adults 18 and older at least once, and during every pregnancy. It is curable in more than 95% of people with a short course of clinician-directed antiviral pills. Seek emergency care right away for signs of advanced liver disease: yellowing of the skin or eyes (jaundice), a swollen or painful belly, confusion or extreme drowsiness, or vomiting blood or passing black, tarry stools — these can signal life-threatening complications and warrant calling 911.
For decades, hepatitis C was a disease with no reliable cure and a grim prognosis — but that changed dramatically with the arrival of direct-acting antiviral medications, which now cure more than 95% of people who complete treatment. Despite this breakthrough, an estimated two million or more Americans are still living with chronic hepatitis C, and a large share do not know they are infected, according to the CDC (exact figures vary by data source and year). The virus silently damages the liver over years, causing cirrhosis and liver cancer in a significant proportion of those who go untreated. Finding the infected, linking them to care, and curing them is now the central challenge — the medical tools exist, but public health implementation lags behind. This guide explains who should be tested, what treatment looks like today, and why acting early matters. For related conditions, see our medical conditions guide.
What Is Hepatitis C?
Hepatitis C is a bloodborne viral infection caused by the hepatitis C virus (HCV), an RNA virus in the Flaviviridae family. There are several major genotypes (and many subtypes) of HCV, which differ in their geographic distribution and, historically, in their response to treatment — though modern pangenotypic medications are effective across all genotypes. Genotype 1 is the most common in the United States.
Upon initial infection, HCV enters liver cells and uses their machinery to replicate. The immune system mounts a response, but HCV is remarkably good at evading it — the virus mutates rapidly, producing a swarm of closely related variants (quasispecies) that stay ahead of immune recognition. As a result, most acutely infected people — roughly three-quarters or more — fail to clear the virus and develop chronic infection. Unlike hepatitis B, there is no vaccine for hepatitis C.
Chronic HCV infection causes progressive liver inflammation and fibrosis (scarring). Over 20 to 30 years, a substantial minority of chronically infected patients develop cirrhosis. Once cirrhosis is established, there is an ongoing annual risk of hepatocellular carcinoma (liver cancer) and of decompensated liver failure — the point at which the liver can no longer keep up, producing complications like ascites, variceal bleeding, and hepatic encephalopathy. According to the WHO, hepatitis C still causes hundreds of thousands of deaths worldwide each year, most of them preventable with testing and treatment.
How Hepatitis C Is Transmitted
Hepatitis C spreads through direct blood-to-blood contact. The most common route of transmission in the United States today is sharing needles, syringes, and other equipment used to inject drugs. The opioid and injection-drug crisis drove a sharp rise in new HCV infections among younger people over the past decade and a half, reversing earlier progress.
Before widespread blood-supply screening began in 1992, blood transfusions and organ transplants were significant sources of infection. Anyone who received a transfusion, blood components, or an organ transplant before July 1992 should be tested for HCV. Healthcare-related transmission through needlestick injuries occurs but is uncommon.
Other, less common routes include perinatal transmission (from a viremic mother to her infant during pregnancy or birth), sexual transmission (risk is low in monogamous heterosexual relationships but higher among men who have sex with men, particularly those with HIV co-infection), tattoos or piercings with unsterile equipment, and sharing personal items that may carry blood, like razors or toothbrushes. Hepatitis C is not spread through casual contact, kissing, hugging, sharing food or water, coughing, or breastfeeding (unless nipples are cracked and bleeding, when experts advise pausing).
Symptoms
Acute hepatitis C infection is usually silent — only a minority of newly infected people develop symptoms. When symptoms do occur, they typically appear weeks after exposure and may include fatigue, nausea, loss of appetite, abdominal pain, dark urine, and jaundice. Because most acute infections cause no symptoms, the majority of new infections go undiagnosed.
Chronic hepatitis C can remain asymptomatic for decades. Some people experience nonspecific symptoms like fatigue, “brain fog,” joint pain, and low mood long before liver disease becomes clinically apparent. HCV can also cause problems outside the liver (extrahepatic manifestations), including mixed cryoglobulinemia (which can cause vasculitis, purpura, and kidney disease), certain kidney conditions, porphyria cutanea tarda, and an increased risk of some lymphomas.
When symptoms of advanced liver disease finally develop — jaundice, ascites, vomiting blood or passing black stools, confusion, easy bruising — cirrhosis has often already been present for years. This long silent phase is exactly why screening and early detection are so critical. By the time symptoms prompt a person to seek care, the window for preventing serious liver damage has frequently closed. Those advanced-disease symptoms, listed in the red-flag box above, are medical emergencies.
Who Should Be Tested
Screening recommendations have expanded to a universal, one-time approach. The CDC recommends that all adults aged 18 and older be tested for hepatitis C at least once in their lifetime, and the USPSTF gives universal screening of adults 18 to 79 a Grade B recommendation — which, under the Affordable Care Act, generally means it is covered by most insurance without cost-sharing. Screening during each pregnancy is also recommended.
Beyond one-time screening, people at higher risk should be tested more often, regardless of age. These include:
- Current or former injection drug users (even if only once, and even long ago)
- Recipients of blood transfusions or organ transplants before July 1992
- People with HIV
- Infants and children born to HCV-positive mothers
- People with unexplained liver disease or elevated liver enzymes
- Healthcare workers after a needlestick or blood exposure
- People who have been incarcerated
- People on long-term hemodialysis
Testing begins with an HCV antibody test, which shows whether you have ever been exposed to the virus. A positive antibody test is confirmed with an HCV RNA test (viral load), which determines whether the virus is currently present. A positive antibody with a negative RNA result usually means a past infection that has cleared (either on its own or through treatment). A positive RNA test confirms active infection that can be treated and cured. Newer point-of-care HCV RNA tests can, in some clinics, deliver results during a single visit — supporting same-day “test-and-treat” models that reduce the number of people lost between diagnosis and care.
The Revolution in Treatment
The development of direct-acting antiviral (DAA) medications is one of the most significant advances in modern medicine. Before DAAs, the standard treatment was pegylated interferon and ribavirin — a regimen that lasted many months, cured only roughly half of patients, and caused severe side effects including flu-like symptoms, anemia, depression, and thyroid problems.
Today’s DAA regimens cure more than 95% of people in as little as 8 to 12 weeks, with mild side effects. DAAs work by directly targeting specific proteins the virus needs to replicate. Different classes target different viral proteins — NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors — and modern pills combine two or three mechanisms for maximal effect.
The most commonly used regimens are pangenotypic, meaning they work against all major genotypes, which simplifies care because extensive genotype testing is often no longer required. According to the AASLD/IDSA HCV Guidance, the choice of regimen and its exact dosing depend on prior treatment history, the presence of cirrhosis, kidney function, and other medications — decisions that belong to your clinician. This guide intentionally does not list specific drug doses; the right regimen is prescribed and monitored by a qualified provider.
What Treatment Is Like
Treatment with DAAs is straightforward compared with the interferon era. Most people take one or a small number of pills once daily for 8 to 12 weeks (occasionally longer in advanced disease). Side effects are generally mild — headache, fatigue, and nausea are the most common — and most people complete treatment without interruption.
Before starting, your provider will assess your degree of liver fibrosis (often using non-invasive tools like elastography or the FIB-4 blood-based score), kidney function, and all your other medications to check for interactions. People with decompensated cirrhosis need more specialized care, because certain regimens are not appropriate for them and they may also require evaluation for liver transplantation alongside antiviral therapy. A safety note that applies to everyone with liver disease: be cautious with alcohol, and use acetaminophen only within limits your clinician approves, since both can add stress to an already-vulnerable liver.
A sustained virologic response (SVR) — undetectable HCV RNA about 12 weeks after finishing treatment — is considered a cure. SVR rates with current regimens consistently exceed 95%, even in groups once labeled “difficult to treat,” including people with cirrhosis, prior treatment failure, and HIV co-infection. Importantly, cure does not create lasting immunity, so reinfection is possible if exposure continues — ongoing risk reduction still matters after cure.
Cost was once a major barrier — the first DAA launched at a list price around $84,000 per course. Competition and generic formulations have brought costs down substantially, and most insurance plans, including Medicaid, now cover DAA therapy; some states have adopted subscription-style purchasing to expand access. Patient-assistance programs from manufacturers can also help. Understanding the financial landscape of hepatitis C treatment and available assistance can help overcome remaining barriers.
After the Cure: What to Know
Achieving SVR dramatically improves outcomes. Cure is associated with a large reduction in overall mortality and in liver-related complications. Liver fibrosis often regresses after cure, and the risk of liver cancer falls substantially — though it does not return to zero, particularly in people who already had cirrhosis before treatment.
People who had advanced fibrosis or cirrhosis before achieving cure need lifelong liver cancer surveillance, typically with an imaging test such as ultrasound roughly every six months. The AASLD/IDSA guidance is clear that cure does not remove the need for ongoing liver cancer screening in patients with significant pre-existing scarring. People without advanced fibrosis generally do not need this ongoing surveillance after cure.
Other post-cure considerations include managing conditions that may persist after cure (such as diabetes, cardiovascular disease, or kidney disease linked to HCV), monitoring for reinfection in people with ongoing exposure risk, and adjusting to life after a long-standing diagnosis is resolved. Many people feel a mix of relief and lingering anxiety, and support from patient advocacy organizations can be valuable.
Hepatitis C and Special Populations
People who inject drugs are the population most affected by hepatitis C and face the greatest barriers to diagnosis and treatment. Historically, many providers and insurers required a period of sobriety before authorizing treatment, but that restriction has been largely abandoned. Current guidance recommends treatment for essentially everyone with chronic hepatitis C, including people who are actively using drugs, without sobriety requirements. Cure rates in this group are comparable to others, and treatment doubles as prevention — curing infected individuals shrinks the pool of virus available to infect others.
People with HIV co-infection have faster liver-disease progression and should be prioritized for treatment; DAAs are highly effective in them, though drug interactions with antiretrovirals must be checked carefully. People with chronic kidney disease, including those on dialysis, can be treated safely with regimens chosen for their kidney function.
For pregnancy, all pregnant people should be screened for HCV. Treating hepatitis C during pregnancy is an area of active research and is generally handled case by case with a specialist rather than as routine practice. Infants born to HCV-positive mothers should be tested per current pediatric guidance; recent recommendations favor checking exposed infants with an HCV RNA test in the first months of life rather than waiting until 18 months, so that infected children can be identified and monitored earlier.
Frequently Asked Questions
Is hepatitis C always curable now?
With currently available DAA therapy, more than 95% of people with chronic hepatitis C are cured after a short course of treatment. Even people with cirrhosis, prior treatment failure, and HIV co-infection reach high cure rates. A small number of people may not respond to the first regimen but can usually be successfully re-treated with an alternative. True, permanent treatment failure is now rare.
Can you get hepatitis C more than once?
Yes. Unlike hepatitis A and B, infection with hepatitis C does not produce lasting protective immunity. If you are cured and then re-exposed (for example, through continued injection drug use), you can become reinfected and would need treatment again. This lack of durable immunity is also part of why an effective HCV vaccine has been so hard to develop.
How long can you have hepatitis C without knowing?
You can carry chronic hepatitis C for decades without symptoms. Many people are diagnosed only when routine blood work shows elevated liver enzymes, or when complications of advanced liver disease appear. This is exactly why universal, one-time screening matters — most people with chronic hepatitis C had no idea they were infected until they were tested.
Is hepatitis C the same as hepatitis A or B?
No. They are caused by different viruses and spread in different ways. Hepatitis A spreads mainly through contaminated food or water; hepatitis B and C spread through blood and body fluids. There are effective vaccines against hepatitis A and B but none for hepatitis C. If you have hepatitis C, your clinician may recommend that you also be vaccinated against hepatitis A and B to protect your liver from additional injury.
Is hepatitis C a sexually transmitted infection?
Hepatitis C can be transmitted sexually, but it is far less efficiently spread this way than hepatitis B or HIV. The risk is low in monogamous heterosexual couples and higher among men who have sex with men, especially those with HIV co-infection or activities that risk blood exposure. The main route of transmission remains blood-to-blood contact, most commonly through shared injection equipment.
Will my liver heal after hepatitis C is cured?
Liver fibrosis often improves after cure, particularly in people with mild to moderate scarring, and even some people with early cirrhosis experience partial regression. However, established cirrhosis — especially decompensated cirrhosis — may involve irreversible damage, and a minority of people may still need a liver transplant despite viral cure. This is why treating early, before advanced fibrosis develops, produces the best outcomes.
Getting Tested and Getting Treated
If you have never been tested, were born in the decades when transfusions went unscreened, have ever injected drugs, or simply want peace of mind, get tested for hepatitis C. It is a simple blood test that can detect a curable disease. If you test positive, know that treatment is short (about 8 to 12 weeks), highly effective (over 95% cure), well tolerated, and increasingly accessible.
Do not let stigma, cost concerns, or past barriers stop you from seeking treatment. The landscape has changed dramatically — sobriety requirements have been dropped in most places, insurance coverage has expanded, generic options have lowered prices, and simplified treatment models let many people be managed by primary care rather than only specialists. Hepatitis C is now a curable disease, and every person cured is one fewer source of transmission. The tools to eliminate hepatitis C exist; the missing piece is making sure everyone who needs testing and treatment actually receives it.
This article is general education, not medical advice, and is not a substitute for care from a qualified clinician. Hepatitis C testing, treatment, and monitoring should be directed by a licensed provider, and antiviral regimens and dosing must be prescribed individually — never self-selected. Seek emergency care for signs of advanced liver disease, such as jaundice, a swollen or painful belly, confusion, or vomiting blood or passing black, tarry stools.
Sources
- CDC (Centers for Disease Control and Prevention), Hepatitis C — cdc.gov
- USPSTF (U.S. Preventive Services Task Force), Hepatitis C Virus Infection Screening — uspreventiveservicestaskforce.org
- AASLD/IDSA, HCV Guidance: Testing, Managing, and Treating Hepatitis C — hcvguidelines.org
- WHO (World Health Organization), Hepatitis C Fact Sheet — who.int
- MedlinePlus (U.S. National Library of Medicine), Hepatitis C — medlineplus.gov